Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL.

6 Although the risks for the 30% eGFR decline and ESRD components were numerically reduced, they did not reach statistical significance in REWIND. 6 A sensitivity analysis of sustained 40% and 50% eGFR declines in REWIND did show a nominally significant improvement with dulaglutide in the median 5.4 year follow‐up in REWIND. 6 In this analysis, we showed for the first time that treatment with exenatide nominally significantly lowered the risk of a composite endpoint—30% eGFR decline or ESRD—that did not include the surrogate albuminuria.

also in 111,027 other papers

6 A sensitivity analysis of sustained 40% and 50% eGFR declines in REWIND did show a nominally significant improvement with dulaglutide in the median 5.4 year follow‐up in REWIND. 6 In this analysis, we showed for the first time that treatment with exenatide nominally significantly lowered the risk of a composite endpoint—30% eGFR decline or ESRD—that did not include the surrogate albuminuria.

also in 7,732 other papers